Drugs /

pgg beta-glucan

Back to Drugs List

Overview

NCI Definition [1]:
An injectable formulation of the polysaccharide beta 1,3/1,6 glucan derived from the cell wall of the yeast Saccharomyces cerevisiae with potential immunomodulating and antineoplastic activities. PGG beta-glucan binds to an alternate site on the neutrophil complement receptor 3 (CR3), priming the neurophil to become cytotoxic when binding to complement on tumor cells via CR3. This agent has been reported to selectively activate immune cells without inducing pro-inflammatory cytokines, potentially reducing potential side effects observed with the induction of broad innate immune repsonses. In addition, PGG beta-glucan may induce hematopoietic progenitor cell (HPC) mobilization.

Clinical Trials

View Clinical Trials for pgg beta-glucan

Pgg beta-glucan has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating pgg beta-glucan, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (1 open).

ALK Fusion, ALK Mutation, and Deficient DNA Mismatch Repair (dMMR) are the most frequent biomarker inclusion criteria for pgg beta-glucan clinical trials.

Breast carcinoma, colorectal adenocarcinoma, and cutaneous melanoma are the most common diseases being investigated in pgg beta-glucan clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pgg Beta-Glucan
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pgg Beta-Glucan
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pgg beta-glucan and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
imprime pgg, poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose beta-glucan, poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose beta-glucan, bth1677
Drug Target(s) [2]:
ITGAM, ITGB2
NCIT ID [1]:
C78463

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.